Simple cholangitis induces extremely and recurrently elevated serum carbohydrate antigen 19-9 level
|
摘要
<正>To the Editor:Thecarbohydrateantigen19-9(CA19-9)isatumormaker which is usually used in biliary and pancreatic malignancies~([1]).However, the specificity of CA19-9 can be reduced by biliary inflammation and other benign diseases~([2]). Generally, the level of
引文
[1] La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, et al. Adjusting CA19-9 values to predict malignancy in obstructive jaundice:influence of bilirubin and C-reactive protein. World J Gastroenterol 2012;18:4150-4155.
[2] Hogendorf P, Skulimowski A, Durczynski A, Kumor A, Poznanska G, Olesna A,et al. A panel of ca19-9, ca125, and ca15-3 as the enhanced test for the differential diagnosis of the pancreatic lesion. Dis Markers 2017;2017:8629712.
[3] Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-4333.
[4] Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9serum levels in obstructive jaundice:clinical value in benign and malignant conditions. Am J Surg 2009;198:333-339.
[5] Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci 2007;52:3140-3142.
[6] He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer 2018;9:3117-3128.
[7] Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T, et al. Differential diagnostic roles of the serum CA19-9, total bilirubin(TBIL)and the ratio of CA19-9 to TBIL for benign and malignant. J Cancer 2018;9:1804-1812.
[8] Shah N, Tetangco E, Arshad HMS, Raddawi H. Mirrizi Syndrome and markedly elevated levels of carbohydrate antigen 19-9 in the absence of malignant disease. Case Rep Gastrointest Med 2017;2017:2416901.
[9] Morinaga T, Imai K, Yamashita YI, Yamao T, Kaida T, Nakagawa S, et al. Multicystic biliary hamartoma with extremely elevated CA19-9:a case report. Scand J Gastroenterol 2017;52:916-919.
[10] Dogan UB, Gumurdulu Y, Golge N, Kara B. Relationship of CA 19-9 with choledocholithiasis and cholangitis. Turk J Gastroenterol 2011;22:171-177.
[11] Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009:8:620-626.
[2] Hogendorf P, Skulimowski A, Durczynski A, Kumor A, Poznanska G, Olesna A,et al. A panel of ca19-9, ca125, and ca15-3 as the enhanced test for the differential diagnosis of the pancreatic lesion. Dis Markers 2017;2017:8629712.
[3] Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-4333.
[4] Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9serum levels in obstructive jaundice:clinical value in benign and malignant conditions. Am J Surg 2009;198:333-339.
[5] Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholangitis. Dig Dis Sci 2007;52:3140-3142.
[6] He C, Zhang Y, Song Y, Wang J, Xing K, Lin X, et al. Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. J Cancer 2018;9:3117-3128.
[7] Liu W, Liu Q, Wang W, Wang P, Chen J, Hong T, et al. Differential diagnostic roles of the serum CA19-9, total bilirubin(TBIL)and the ratio of CA19-9 to TBIL for benign and malignant. J Cancer 2018;9:1804-1812.
[8] Shah N, Tetangco E, Arshad HMS, Raddawi H. Mirrizi Syndrome and markedly elevated levels of carbohydrate antigen 19-9 in the absence of malignant disease. Case Rep Gastrointest Med 2017;2017:2416901.
[9] Morinaga T, Imai K, Yamashita YI, Yamao T, Kaida T, Nakagawa S, et al. Multicystic biliary hamartoma with extremely elevated CA19-9:a case report. Scand J Gastroenterol 2017;52:916-919.
[10] Dogan UB, Gumurdulu Y, Golge N, Kara B. Relationship of CA 19-9 with choledocholithiasis and cholangitis. Turk J Gastroenterol 2011;22:171-177.
[11] Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009:8:620-626.